HRAS and neoplasm: The xenograft SJRHB000026 [67] (HRAS G13R, PIK3CA missense mutation) had less profound tumor growth inhibition compared to other HRAS-mutant xenografts, which may be at least in part due to the concomitant PIK3CA mutation and the emergence of early adaptive or acquired resistance.